Recursion Announces Board Transition
Recursion, a clinical-stage TechBio company focused on AI-driven drug discovery, announced that its founder Chris Gibson, Ph.D., will not seek re-election to the Board of Directors after June 2026 but will continue as a strategic advisor. The company emphasizes continuity and long-term value creation under CEO Najat Khan's leadership, advancing its…